<DOC>
	<DOCNO>NCT00319956</DOCNO>
	<brief_summary>The hypothesis study administration azithromycin ventilate premature infant decrease incidence severity BPD . The purpose study determine Azithromycin treatment beneficial prevention bronchopulmonary dysplasia preterm infant .</brief_summary>
	<brief_title>Trial II Lung Protection With Azithromycin Preterm Infant</brief_title>
	<detailed_description>The survival preterm infant increase dramatically associate increase BPD . The incidence BPD among extremely low birthweight infant range 45 % 90 % . Development BPD associate antenatal ( maternal chorioamnionitis often due Ureaplasma related BPD ) postnatal complication ( oxygen toxicity , barotrauma , late onset infection ) . These insult appear lead inflammatory response resultant arrest normal alveolar vascular development . Multiple human study support role inflammation development BPD . Evaluating medication could decrease inflammation BPD , minimal side effect , could significantly improve morbidity prematurity financial burden incur parent . Macrolide antibiotic ( erythromycin azithromycin ) show anti-inflammatory property independent antimicrobial property . Azithromycin potential decrease severity ventilator-induced pulmonary inflammation commonly see BPD .</detailed_description>
	<mesh_term>Bronchopulmonary Dysplasia</mesh_term>
	<criteria>birthweight less 1250 gram admit UK NICU mechanical ventilation within first 72 hour life confirm sepsis blood culture multiple congenital anomaly know syndrome intrauterine growth retardation birthweight less 10 % ile gestational age ROM &gt; 7 day</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>72 Hours</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>premature infant</keyword>
	<keyword>respiratory distress syndrome</keyword>
	<keyword>mechanical ventilation</keyword>
</DOC>